CINECA IRIS Institutional Research Information System

LORUSSO, LOREDANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.667
EU - Europa 1.429
AS - Asia 1.344
SA - Sud America 211
Continente sconosciuto - Info sul continente non disponibili 101
AF - Africa 83
OC - Oceania 7
Totale 5.842
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.607
SG - Singapore 434
IT - Italia 427
CN - Cina 395
DE - Germania 337
SE - Svezia 185
HK - Hong Kong 182
BR - Brasile 164
GB - Regno Unito 115
VN - Vietnam 105
AT - Austria 78
BG - Bulgaria 68
FR - Francia 53
RU - Federazione Russa 43
IN - India 42
JP - Giappone 40
CA - Canada 37
FI - Finlandia 36
CI - Costa d'Avorio 26
TR - Turchia 25
SN - Senegal 21
KR - Corea 20
MA - Marocco 20
NL - Olanda 20
BD - Bangladesh 15
IQ - Iraq 15
AR - Argentina 13
MX - Messico 12
PL - Polonia 12
PH - Filippine 11
UZ - Uzbekistan 10
UA - Ucraina 9
SA - Arabia Saudita 8
CH - Svizzera 7
CL - Cile 7
CO - Colombia 7
ES - Italia 7
ZA - Sudafrica 7
ID - Indonesia 6
LT - Lituania 6
VE - Venezuela 6
AU - Australia 5
CZ - Repubblica Ceca 5
EC - Ecuador 5
LB - Libano 5
PK - Pakistan 5
IR - Iran 4
RO - Romania 4
UY - Uruguay 4
EG - Egitto 3
IL - Israele 3
KZ - Kazakistan 3
MY - Malesia 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
AL - Albania 2
EE - Estonia 2
IE - Irlanda 2
JM - Giamaica 2
JO - Giordania 2
NP - Nepal 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TW - Taiwan 2
A1 - Anonimo 1
AZ - Azerbaigian 1
BB - Barbados 1
BE - Belgio 1
BH - Bahrain 1
BO - Bolivia 1
CR - Costa Rica 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
KG - Kirghizistan 1
KI - Kiribati 1
LY - Libia 1
MM - Myanmar 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
SR - Suriname 1
SY - Repubblica araba siriana 1
Totale 5.742
Salva come PNG Salva come JPEG
Città #
Ashburn 345
Singapore 249
Dallas 240
Hong Kong 180
Milan 179
Chandler 174
San Jose 172
Fairfield 149
Santa Clara 137
Woodbridge 130
Seattle 86
Houston 85
New York 84
Shanghai 76
Vienna 73
Sofia 67
Los Angeles 62
Beijing 59
Council Bluffs 59
Cambridge 54
Wilmington 54
Ann Arbor 52
Munich 50
London 39
Hefei 37
Florence 36
Princeton 36
Boardman 33
Ho Chi Minh City 31
Rome 31
Tokyo 31
Frankfurt am Main 27
Lauterbourg 27
Abidjan 26
Lawrence 25
Dearborn 22
Dakar 21
Bremen 20
Medford 20
Seoul 19
Hanoi 18
Pisa 18
São Paulo 18
Turku 17
Redondo Beach 16
Ottawa 13
Buffalo 12
Casablanca 12
Denver 12
Dong Ket 12
Phoenix 12
Redwood City 12
San Diego 11
Serra 11
Atlanta 10
Des Moines 10
Helsinki 10
Nanjing 10
Warsaw 10
Baghdad 9
Fuzhou 9
Nuremberg 9
Orem 9
Tashkent 9
Washington 9
Chicago 8
Istanbul 8
Montreal 8
Ogden 8
Salt Lake City 8
Toronto 8
Amsterdam 7
Brooklyn 7
Lancaster 7
Quanzhou 7
San Francisco 7
Belo Horizonte 6
Izmir 6
Nanchang 6
Redmond 6
Scandicci 6
Shenyang 6
Stockholm 6
Ankara 5
Boston 5
Chiesina Uzzanese 5
Cleveland 5
Johannesburg 5
Manila 5
Tianjin 5
Bern 4
Brno 4
Chengdu 4
Delhi 4
Dhaka 4
Düsseldorf 4
Guangzhou 4
Kyiv 4
Mumbai 4
Paris 4
Totale 3.795
Salva come PNG Salva come JPEG
Nome #
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 249
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 240
Thyroid autoimmunity, thyroglobulin autoantibodies and thyroid cancer prognosis 232
Targeted Therapy in Thyroid Cancer: State of the Art 227
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 218
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 215
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 213
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 209
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 206
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 206
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 206
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 201
Il carcinoma tiroideo: nuove prospettive terapeutiche. 195
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer 193
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 181
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 180
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates 178
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features 174
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 174
Systemic treatment of advanced, metastatic, medullary thyroid carcinoma 168
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 165
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 165
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 164
Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib 157
Carcinoma tiroideo e gravidanza. 146
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 144
Ret mutated C-cells proliferate more rapidly than non-mutated neoplastic cells 135
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 131
Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer 128
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response 122
Hand-foot syndrome in sorafenib and lenvatinib treatment for advanced thyroid cancer 100
null 70
null 54
Risultati dello studio di fase III, randomizzato, controllato, in doppio cieco, Sorafenib vs Placebo nel trattamento del carcinoma differenziato della tiroide (CDT) localmente avanzato o metastatico, refrattario al 131I, in progressione. 42
Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment 25
Determinants of Health-Related Quality of Life in Differentiated and Poorly Differentiated Thyroid Cancer Patients With Structural Incomplete Response: A Multicenter Cross-Sectional Study 16
Follicular thyroid cancer in lenvatinib therapy complicated by tracheoesophageal fistula treated with pharyngo-laryngo-esophagectomy and definitive tracheostomy 13
Totale 5.842
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.599
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.599
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022299 0 6 2 13 62 47 10 16 25 19 22 77
2022/2023653 73 104 53 65 63 76 6 36 105 14 48 10
2023/2024519 60 70 78 47 67 87 19 8 6 7 22 48
2024/20251.198 9 42 13 64 121 106 108 65 113 144 138 275
2025/20261.772 162 266 170 183 183 125 246 66 128 159 53 31
2026/2027143 55 88 0 0 0 0 0 0 0 0 0 0
Totale 5.842